These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 20882037)
1. Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. Fusi A; Reichelt U; Busse A; Ochsenreither S; Rietz A; Maisel M; Keilholz U J Invest Dermatol; 2011 Feb; 131(2):487-94. PubMed ID: 20882037 [TBL] [Abstract][Full Text] [Related]
2. Co-expression of putative cancer stem cell markers, CD133 and Nestin, in skin tumors. Sabet MN; Rakhshan A; Erfani E; Madjd Z Asian Pac J Cancer Prev; 2014; 15(19):8161-9. PubMed ID: 25339000 [TBL] [Abstract][Full Text] [Related]
3. CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans. Thomas-Pfaab M; Annereau JP; Munsch C; Guilbaud N; Garrido I; Paul C; Brousset P; Lamant L; Meyer N J Dermatol Sci; 2013 Feb; 69(2):105-13. PubMed ID: 23219141 [TBL] [Abstract][Full Text] [Related]
4. Immuno-expression of human melanoma stem cell markers in tissues at different stages of the disease. Sharma BK; Manglik V; Elias EG J Surg Res; 2010 Sep; 163(1):e11-5. PubMed ID: 20638684 [TBL] [Abstract][Full Text] [Related]
6. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer. Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500 [TBL] [Abstract][Full Text] [Related]
7. Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance. Kim HS; Yoo SY; Kim KT; Park JT; Kim HJ; Kim JC Int J Clin Exp Pathol; 2012; 5(8):754-61. PubMed ID: 23071857 [TBL] [Abstract][Full Text] [Related]
8. Expression of CD133 and other putative stem cell markers in uveal melanoma. Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792 [TBL] [Abstract][Full Text] [Related]
9. CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines. Sana J; Zambo I; Skoda J; Neradil J; Chlapek P; Hermanova M; Mudry P; Vasikova A; Zitterbart K; Hampl A; Sterba J; Veselska R Anal Cell Pathol (Amst); 2011; 34(6):303-18. PubMed ID: 22156015 [TBL] [Abstract][Full Text] [Related]
10. Increased expression of stem cell markers in malignant melanoma. Klein WM; Wu BP; Zhao S; Wu H; Klein-Szanto AJ; Tahan SR Mod Pathol; 2007 Jan; 20(1):102-7. PubMed ID: 17143262 [TBL] [Abstract][Full Text] [Related]
11. [Correlative study of distribution of brain tumor stem cell with micro-vascular system]. Li MW; Niu CS Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050 [TBL] [Abstract][Full Text] [Related]
12. The pathological characteristics of glioma stem cell niches. He H; Li MW; Niu CS J Clin Neurosci; 2012 Jan; 19(1):121-7. PubMed ID: 22178090 [TBL] [Abstract][Full Text] [Related]
13. Expression of neural stem cell surface marker CD133 in balloon cells of human focal cortical dysplasia. Ying Z; Gonzalez-Martinez J; Tilelli C; Bingaman W; Najm I Epilepsia; 2005 Nov; 46(11):1716-23. PubMed ID: 16302851 [TBL] [Abstract][Full Text] [Related]
14. Nestin and vimentin colocalization affects the subcellular location of glucocorticoid receptor in cutaneous melanoma. Lai S; Piras F; Spiga S; Perra MT; Minerba L; Piga M; Mura E; Murtas D; Demurtas P; Corrias M; Maxia C; Ferreli C; Sirigu P Histopathology; 2013 Feb; 62(3):487-98. PubMed ID: 23072594 [TBL] [Abstract][Full Text] [Related]
15. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas. Bexell D; Gunnarsson S; Siesjö P; Bengzon J; Darabi A Int J Cancer; 2009 Jul; 125(1):15-22. PubMed ID: 19291792 [TBL] [Abstract][Full Text] [Related]
16. Clonal dominance of CD133+ subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma. Sharma BK; Manglik V; O'Connell M; Weeraratna A; McCarron EC; Broussard JN; Divito KA; Simbulan-Rosenthal CM; Rosenthal DS; Zapas JL Int J Oncol; 2012 Nov; 41(5):1570-6. PubMed ID: 22922842 [TBL] [Abstract][Full Text] [Related]
17. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dahlrot RH Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629 [TBL] [Abstract][Full Text] [Related]
18. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713 [TBL] [Abstract][Full Text] [Related]
19. What is the clinical value of cancer stem cell markers in gliomas? Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the hair follicle stem cell marker nestin in patients with malignant melanoma. Tanabe K; Amoh Y; Kanoh M; Takasu H; Sakai N; Sato Y; Katsuoka K Eur J Dermatol; 2010; 20(3):283-8. PubMed ID: 20156773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]